Neoleukin Therapeutics Provides Update on COVID-19 Impact on Corporate and Clinical Development Activities

SEATTLE, April 09, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. Neoleukin (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to designde novoprotein therapeutics, today provided an update on the impacts of COVID-19 on the companys corporate and research operations.